FDA panel conflicts of interest
This article was originally published in The Gray Sheet
Executive Summary
Reconciled FY 2006 FDA appropriations bill passes the House Oct. 28 with a "very watered-down" version of an advisory committee conflict-of-interest (CoI) provision, according to Rep. Maurice Hinchey (D-N.Y.), who succeeded in adding a CoI amendment to the original House bill in June. The final language requires that panel member conflicts of interest and waivers for conflicts be posted on FDA's website at least 15 days prior to a meeting or as soon as possible if the conflict is identified closer to the meeting date. Hinchey's amendment would have prohibited FDA from granting CoI waivers (1"The Gray Sheet" June 13, 2005, In Brief)...